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Abstract Malcolm Rowland has greatly facilitated an understanding of drug
structure–pharmacokinetic relationships using a physiological perspective. His view
points, covering a wide range of activities, have impacted on my own work and on
my appreciation and understanding of our science. This overview summarises some
of our parallel activities, beginning with Malcolm’s work on the pH control of
amphetamine excretion, his work on the disposition of aspirin and on the application
of clearance concepts in describing the disposition of lidocaine. Malcolm also spent
a considerable amount of time developing principles that deﬁne solute structure and
transport/pharmacokinetic relationships using in situ organ studies, which he then
extended to involve the whole body. Together, we developed a physiological
approach to studying hepatic clearance, introducing the convection–dispersion
model in which there was a spread in blood transit times through the liver
accompanied by permeation into hepatocytes and removal by metabolism or
excretion into the bile. With a range of colleagues, we then further developed the
model and applied it to various organs in the body. One of Malcolm’s special
interests was in being able to apply this knowledge, together with an understanding
of physiological differences in scaling up pharmacokinetics from animals to man.
The description of his many other activities, such as the development of clearance
concepts, application of pharmacokinetics to the clinical situation and using
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Introduction
I would like to acknowledge from the outset that I have been privileged to be an
invited speaker at the 70th birthday of one of my mentors, Malcolm Rowland, who
has greatly assisted in the development of my views about science and life. There are
a number of other Australians, including Felix Bochner, Garry Graham, Andrew
McLachlan, Allan Evans and Lloyd Sansom, who have also worked with Malcolm
and would like to have been here. There are many others who have been inﬂuenced
by your many sojourns ‘‘Down Under’’. Malcolm was successful in attracting one of
us, Leon Aarons, to work with him at Manchester from postdoctoral studies to today,
a collaboration that has resulted in many pivotal papers in our discipline. In this
paper, I highlight the inﬂuence Malcolm has had on my own research, especially the
role of solute structure on pharmacokinetics. I begin with the physiological
perspective Malcolm brought to pharmacokinetics and how he used that knowledge
to deﬁne solute structure pharmacokinetic relationships. My perspective is an
intensely personal one in that I started in membrane transport and was inﬂuenced by
Malcolm’s thinking early on, I had the pleasure to work with Malcolm whilst on my
only sabbatical leave, to watch Malcolm’s continuing journey but, at the same time,
working independently to reach where I think we are now.
Physiological pharmacokinetics
Malcolm’s early studies were concerned with the assay of a number of drugs but
three ‘‘stand out’’ in my mind, perhaps because I have also worked on them. The
ﬁrst is amphetamine/methylamphetamine which Malcolm analysed in urine by gas
chromatography and showed that their excretion was highly dependent on urine pH
[1, 2] (Fig. 1a). Malcolm’s future focus on physiological pharmacokinetics is
undoubtedly nurtured by these studies showing that amphetamine renal excretion is
dependent on both urine ﬂow rate and urine pH and this can change greatly over a
24 h period. Less well known is my work on the percutaneous absorption of phenol
in the rat, mainly because it was published in a local journal that was not in Current
Contents or Index Medicus, the Australian Journal of Pharmaceutical Science.
Phenol was widely used in Calamine Lotion and had a similar assay problem to
amphetamine—it was volatile and poor recovery resulted if evaporated to dryness
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such losses was to apply the technique used by Malcolm for amphetamine. In my
case, this involved extraction of phenol from blood using diethyl ether and
evaporation to 20 ll in a 100 ll nipple at the end of a tube and injecting 10 ll. I
found that phenol displayed bi-exponential kinetics after intravenous administration
and, importantly, that the anaesthetic greatly affected phenol’s intravenous
disposition and percutaneous absorption. As shown in Fig. 1b, there are much
higher phenol plasma levels for urethane than for ethyl ether. There are two effects
induced by the anaesthetics—alterations in blood ﬂow at the absorption site and
alterations in phenol clearance. Urethane is a dermal vasodilator whereas ethyl ether
is a vasoconstrictor [3]. Phenol is rapidly metabolised by conjugation through the
sulphate and glucuronide pathways and these are inhibited by diethyl ether but not
by urethane [4], explaining the continued accumulation over time for ether.
The second ‘‘stand-out’’ drug that Malcolm studied during his postdoctoral
studies at the University of San Francisco with Sid Riegelman was aspirin [5], a
compound that I also did a number of studies on, including deﬁning its disposition
in elderly and alcoholic subjects [6], extrahepatic metabolism [7], its effects on
platelets [8] and in describing the apparent autoinduction of the salicyluric acid
pathway on chronic ingestion of high doses [9, 10]. We also followed up on Tom
Tozer and colleagues’ steady state work on salicylate clearance being determined by
saturable protein binding and metabolism [11] to model these effects during a single
dose [12]. Perhaps, one of the most fulﬁlling aspects of our work on aspirin is that a
dose form we helped to develop [8] as a prophylaxis for heart attacks and stroke,
Cartia
 (Glaxo-Smith-Kline) is still on the market today. Malcolm, Leon Aarons
and others also showed that aspirin absorption was faster in women after oral
administration but slower after intramuscular administration [13]. They also deﬁned
the kinetics of aspirin hydrolysis by albumin [14]. These early studies, many of
which we conducted on ourselves naive in terms of today’s ethics requirements,
have not all been without problems. One of my colleagues suffered from a most
profound, long and sustained Arthus reaction (i.e. a rare but rather severe and
immediate nonatopic hypersensitivity reaction) when we each injected each other
with diluted wasp venom to see if topical aspirin and other products lessened the
resulting inﬂammatory response [15]. Another Australian colleague, Felix Bochner,
obtained his tinnitus in taking high doses of salicylate whilst on sabbatical with
Malcolm [16].
Figure 1c and d shows two illustrations of Malcolm’s work with aspirin.
Figure 1c shows the importance of blood ﬂow in oral absorption. Here, blood
sampling continued to be undertaken in one of their subjects who felt faint. It is
clear that there is impairment of aspirin absorption in this situation [17]. The second
example shows that there may be a delay in reaching a target site of action is distant
from the plasma, contributing to a delay in response. Here, the peaking of aspirin in
synovial ﬂuid occurs some time after that in plasma (Fig. 1d) [18]. One of the
‘‘follow-up’’ questions that I studied was how did posture and sleep affect
pharmacokinetics and, if the changes observed meant a need to change dosing
regimens? The ﬁrst drug we studied, amoxicillin, showed the most pronounced
postural effect with the plasma AUC being signiﬁcantly greater in the upright
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exercise (subjects were allowed to walk whilst in the upright position) possibly
added to the postural effect of an increase in real blood ﬂow and higher active renal
secretion of amoxicillin. We did not ﬁnd differences when we examined benzyl
penicillin given intramuscularly [20] or intravenously [21]. Lying down and
sleeping had the effect of delaying the absorption of paracetamol [22].
The third ‘‘stand out’’ compound is lidocaine. Here, Malcolm and colleagues
showed that an altered clearance can lead to enhanced plasma levels and, in heart
failure, disposition effects further compounds lidocaine pharmacokinetics. Fig-
ure 1e and f shows the altered disposition of lidocaine in heart failure after
intravenous bolus and infusion administration, examples I have often used in my
teaching. Here, the reduced body perfusion in cardiac failure leads to reduction in
the apparent distribution volume by about one third. Lidocaine clearance in heart
failure is also reduced by about one third. An important ﬁnding is that the dependent
variable half life (= 0.693 9 apparent distribution volume/clearance) is effectively
unchanged in heart failure [23, 24]. A reduced dosing is indicated with both a
reduced clearance (target steady state plasma concentration = infusion rate/
clearance) and a reduced volume of distribution (initial plasma concentra-
tion = dose/apparent distribution volume), whereas the lack of change in half life
would predict that no change in lidocaine dosing was necessary. It is noted that
physiological pharmacokinetic principles does not predict a reduced volume of
distribution at steady state in heart failure for all drugs. For example, cardiac failure
leads to a reduction in the clearance of midazolam but not in its steady state
distribution volume [25]. In contrast to the signiﬁcant changes in lidocaine
pharmacokinetics in cardiac failure, no signiﬁcant changes in lidocaine pharmaco-
kinetics are observed in renal failure; whereas, in liver disease, only lidocaine
clearance is impaired, leading in turn to an increased half life (Fig. 1g).
Structure transport relationships in absorption and distribution
Most target tissues contain vasculature, interstitium, and cells, and represent-
ing them as a single compartment is physiologically naive. [26].
Fig. 1 a Effect of urine pH and urine output on the urinary excretion of amphetamine in man, after oral
administration of 10 mg (?)-amphetamine sulphate (reprinted by permission from Macmillan Publishers
Ltd: Nature [1], copyright 1965). b Blood levels of phenol in the rat observed during the cutaneous
application of phenol (1%) under different anaesthetics [169]. c Plasma aspirin concentrations after
650 mg aspirin as a solution on two separate occasions. On the second occasion (open circle), the subject
felt nervous and faint while the 10 min blood sample was being taken. It is apparent that there is
impairment in absorption on this occasion, probably ‘‘due to decreased motility of, and circulation to, the
GIT’’ (adapted from [17]). d Plasma and synovial ﬂuid aspirin concentrations in one patient after oral
ingestion of aspirin, ASA, 20 grains (1,296 mg). Time zero corresponds to 2.5 h after the patient had
inadvertently taken 10 grains (648 mg) of aspirin (adapted from [18]). e Plasma levels of lidocaine (±SD,
n = 7) after 50 mg intravenous bolus to control and heart failure (adapted from [24]). f Plasma levels of
lidocaine after infusion to a normal patient and in a patient of same size with heart failure (adapted from
[24]). g Effect of heart failure, liver disease, and renal failure on lidocaine disposition parameters in man
(adapted from [24])
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123In my view, one of Malcolm’s key contributions was his work with Rene Levy in
which he explored structure penetration relationships for the subcutaneous
absorption kinetics of local anaesthetics [27]. Here, lidocaine was the lead
compound. Malcolm and Rene used a relatively simple pharmacokinetic model
involving uptake from a subcutaneous solution into a membrane and thence
clearance into the systemic circulation (Fig. 2a). He showed that for a series of
synthesised lidocaine derivatives disappearance was characterised by increased
membrane uptake and uptake into the systemic circulation with lipophilicity
(Fig. 2b). We used this model to show that solute lipophilicity and surface area also
deﬁned the uptake of preservatives into plastic containers and loss into the
atmosphere during storage [28] (Fig. 2c). We also used Levy and Rowland’s
experimental approach [27] to study the deep tissue penetration of a number of
compounds after dermal application, including salicylate, and showed that direct
penetration to deeper tissues occurred early on but that levels at longer times were
mainly due to recirculatory events [29]. Later, we became interested in using
subcutaneous infusions to manage rehydration of elderly subjects and had the
opportunity to use radiolabelled tracers and imaging to better deﬁne the kinetics of
subcutaneous absorption in man [30, 31].
An elegant part of Malcolm and Rene’s subcutaneous absorption kinetics studies
was to show that blood ﬂow and ionisation were components in the subcutaneous
absorption kinetics. As shown in Fig. 2d, there was negligible absorption for
lidocaine from subcutaneous solutions with no blood ﬂow (post-mortem studies)
and when the lidocaine was in an ionised form (pH 5.42). On the other hand, initial
uptake an unionised lidocaine (pH 7.95) was faster than the partially ionised
lidocaine in vivo and the later disappearance from a pH 7.95 solution in vivo was
greater than for post-mortem studies showing the importance of subcutaneous blood
ﬂow in determining clearance from the site into the systemic circulation. We used a
similar approach to show that vasoconstrictors modiﬁed the salicylate concentra-
tions in deeper tissues after dermal application to be intermediate between in vivo
and post-mortem tissues (Fig. 2e). We also used the lack of blood ﬂow induced
changes in interferon disappearance from dermal sites to show that the dermal
absorption of larger molecules, like interferon, was most likely absorbed via the
lymphatics [32]. The role of lymphatics in solute disposition has been extensively
studied by my Australian colleagues [33, 34]. Finally, in contrast to the absorption
ﬁndings shown for subcutaneous and dermal administration of aqueous solutions,
the uptake of compounds from synovial ﬂuid in man decreases with increasing
lipophilicity. Here, binding to synovial ﬂuid protein dominates and, indeed, for
Fig. 2 a Compartmental model representation of drug loss from solutions at subcutaneous site and stored
in plastic containers (adapted from [27]). b In vivo biphasic disappearance curves of lidocaine and
compound I(F) (pH 7.95) and compound III (CH3) (pH 7.95) after subcutaneous application (adapted
from [27]). c Representative plots of fraction of solute remaining in aqueous solution in polyethylene
containers stored at 37 ± 1C[ 28]. d In vivo and postmortem lidocaine disappearance curves from
subcutaneous solutions in the rat (adapted from [27]). e Vasoconstriction and penetration: salicylic acid
2 h after dermal application [170]. f Fraction remaining versus time plot for paracetamol, salicylate,
diclofenac and albumin after injection of a mixture of all solutes into the knee effusions of the ﬁve
subjects studied [35]. (P and K are octanol-water and hexane-water partition coefﬁcients)
c
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123diclofenac about half its clearance occurs as diclofenac bound to albumin (Fig. 2f)
[35]. A similar ﬁnding was reported by Malcolm’s group but this time using an air
pouch in the rat [36]. They concluded that a perfusion rate limitation probably
applied to the uptake of NSAIDs into the pouch during the ﬁrst 2 h when albumin
ﬂux into the pouch is not enough to affect the permeability of the NSAIDs. The
effective ﬂux of the NSAIDs is lowered when the albumin concentration in the
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123pouch increases after 5 h. In a later paper, they suggested that drug transport into the
site cannot be based on unbound drug only and must also include the simultaneous
ﬂux of drug bound to albumin, which enters the target site due to increased vascular
permeability associated with the inﬂammatory response [37].
The famous German writer Goethe is said to have remarked ‘‘Whatever you
can do or dream you can, begin it. Boldness has genius, power and magic in it.’’
[180]. Looking back, this certainly applies in my own studies of absorption and
pharmacokinetics of drugs and toxins across the skin and the uptake of drugs into
plastics. My own scientiﬁc journey into transport-structure relationships began
during an undergraduate pharmacy research project. One of our objectives was to
quantify the uptake of drugs and preservatives into the plastic surface of eye dropper
bottles that had been sterilised in the autoclave. We showed that solute properties,
the nature of the container and the role of the area:solution volume ratio were
determinants of drug loss [38]. My PhD studies in topical absorption was driven by
an interest in making topical creams and a 1942 publication by Zondek [181], that
showed topical chloroxylenol could be effective in treating urinary tract infections.
It was during this time that Les Benet introduced me to Laplace Transforms in
pharmacokinetics, John Wagner interested me in the modelling of nonlinear
processes and one of Malcolm’s younger PhD colleagues from Arnold Beckett’s
laboratory in London, Ted Triggs, taught me nonlinear regression with NonLin,
leading in part to a paper we published in Nature [39]. A key ﬁnding, in our work on
the percutaneous absorption of different phenolic compounds, was that penetration
of phenolic compounds increased in a parabolic fashion with lipophilicity (Fig. 3a)
[40]. At that time, I had used thermodynamic studies to argue that the non-parabolic
behaviour was due to the more polar ‘‘aqueous’’ layers below the skin providing an
additional resistance to the penetration of the more lipophilic solutes. Russ Potts and
Richard Guy subsequently reanalysed my data with others and concluded that the
parabolic behaviour was most likely due to these more lipid solutes also being larger
in size [41]. We then showed that molecular size is the dominant determinant for
the maximum ﬂux of solutes through the skin (Fig. 3b) [42]. Hence, when we
re-examined the percutaneous absorption of a series of phenolic compounds with
almost identical size and hydrogen bonding, we found that the permeability
coefﬁcient is linearly related to lipophilicity (Fig. 3c) [43]. An important outcome
of this work was the observation of a parabolic relationship between maximum ﬂux
and lipophilicity for solutes of approximately the same size (Fig. 3d) but that the
estimated diffusivity was independent of lipophilicity (Fig. 3e) and the maximum
ﬂux was directly related to the solubility in the stratum corneum (Fig. 3f). Thus,
parabolic relationship between maximum ﬂux and lipophilicity reﬂects a maximum
solubility that exists for solutes in the stratum corneum lipids [43]. Our ﬁnding
differs from conventional thinking that polar solutes cannot partition into a
membrane while lipid solutes partition out of a membrane when a solute crosses
several membranes and aqueous interstitial ﬂuids. This conventional view has long
been advocated by many [44–46]. Figure 3 illustrates the overturning of a long held
scientiﬁc paradigm through a key experiment. It also reinforces advice given to me
as a young PhD student by a then faculty member, Jack Thomas. His advice was that
all quality data can help, even if the interpretation is incorrect—as that data may
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123Fig. 3 a Relationship between permeability of phenolic compounds through human epidermis and their
lipophilicity as deﬁned by their logarithm of octanol-water partition coefﬁcient, log P (adapted from
[40]). b Relationship between maximum ﬂux, Jmax and solute size, as deﬁned by molecular weight MW,
for solutes from aqueous solution through human epidermal membranes [42]. c Variation in permeability
coefﬁcient (kp), with experimental log octanol-water partition coefﬁcient (log P)( r
2 = 0.81) [43].
d Dependence of maximum ﬂux Jmax on log P for penetration of phenolic compounds through excised
human epidermal membranes using Franz cells [43]. e Variation of diffusivity (D) with experimental log
P [43]. f Dependence of maximum ﬂux Jmax on stratum corneum solubility Sc for penetration of phenolic
compounds through excised human epidermal membranes [43]
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proven to be so correct, particularly in pharmacokinetic modelling where George
Box, the industrial statistician, is frequently quoted as having said ‘all models are
wrong, some are useful’. One of my other mentors, Gordon Flynn, with whom I also
have the privilege of writing a textbook soon to be published [47], has also pointed
out that perhaps a particular model is never really wrong, it just applies to a different
jurisdiction. Hence, the dependence of skin maximum ﬂux on skin solubility
probably dominates for the low to moderately lipophilic compounds (0\log
P\4) that we studied. Other mechanisms are more likely to dominate for very
polar solutes (e.g. via appendages or polar head group pathway [48]) and very
lipophilic solutes (signiﬁcant additional barrier resistance from the more polar
epidermis [49], dermis [50] and aqueous layer [40, 44]. As Gordon Flynn, points out
[47]: ‘This (latest work) seems to be the ﬁrst clear demonstration of how biological
permeability, at its maximum, is directly dependent on solubility.’
However, as is often the case, the real clinical outcomes occur by serendipity. In
other words, one normally ﬁnds the unexpected in trying to understand something
else. One of my more profound experiences occurred in early 1975, when our
hospital clinicians began infusions of nitroglycerin as a treatment for cardiac failure.
Initially the infusions appeared successful but, within 30 min, efﬁcacy was lost.
Some efﬁcacy could be regained if the infusion rate was increased but never as
much as the clinicians anticipated. When studies were repeated a week later no
response at all was obtained. The question became: what was happening? We
deduced that one of two possibilities were possible. Either the drug was not getting
to the patient as anticipated or there was something happening in the body to the
nitroglycerin. We therefore did some simulated infusions and measured what came
out of the infusion system at different ﬂow rates. The results obtained are shown in
Fig. 4a. It is evident that 100% was delivered initially but then became very low
when low ﬂow rates were used and somewhat higher when higher ﬂow rates were
employed. Hence, clearly, there was uptake of nitroglycerin into the plastic of the
infusion sets [51]. Later studies showed that uptake was occurring into both the
polyvinyl chloride infusion bag and into the giving set [182]. Indeed, the reason why
there was no delivery a week later was that the hospital’s pharmacy had decided to
make up the nitroglycerin infusions in the infusion bags 24 h earlier to have stock
on hand as needed—without realising this would effectively deactivate the
nitroglycerin as it enabled it even more time to diffuse into the plastic infusion
bag. The importance of this ﬁnding is that we then went on to show that a number of
other drugs including isosorbide dinitrate [52], diazepam, various phenothiazines
etc. [53, 54] are also lost into these systems and that diffusion in the plastic was a
major mechanism for loss [55]. Importantly, our work paralleled Levy and
Rowland’s [27], in that we found it was the unionised and not ionised solutes that
were lost into infusion bags on storage [56]. Thus, the pH of the infusion solution
and pKa of the solute are key determinants for loss on storage. But, returning to the
earlier story, the cardiologists were not happy in just knowing the reason. They
wanted to know how to give nitroglycerin without such problems. The solution
turned out to be the same one we know needs to be applied in minimising lipophilic
drug loss for solutes stored in aqueous solutions in plastic containers—the plastic
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to using a polyoleﬁn system, later commercialised by Tridil
, where there was
negligible loss on infusion (Fig. 4b).
Malcolm and a then young postdoc Andrew MacLachlan, also ventured into the
area of using regional administration to more effectively target drugs by applying
pharmacokinetic principles [26]. Earlier studies had initially used a well-stirred
pharmacokinetic models and transport by blood ﬂow. Later studies included a
permeability barrier as well as a tissue partition coefﬁcient. Together, they showed
that a positive Drug Targeting Index (DTI), or Selective Advantage could be
achieved using intra-arterial administration. They showed that DTI depended on the
relative permeability of unbound drug across the vascular and cellular membranes in
the target tissue relative to the tissue blood ﬂow rate and that the ﬂux of bound
drug between the vascular and interstitial spaces of the target could also affect the
DTI [26].
Fig. 4 a Effect of ﬂow rate on percentage of nitroglycerin in solutions emerging from plastic infusion
sets (adapted from [51]). b Percentage of nitroglycerin emerging after passage through 80 cm
polyethylene tubing attached to glass syringe (adapted from [51])
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‘‘An overall objective of physiological modelling is to simulate the complete
system through a fundamental study of its component parts.’’ [57]
Malcolm also had a particular interest in deﬁning solute structure pharmacoki-
netic relationships in terms of the underlying tissue volumes, blood ﬂows and
clearances. Using lidocaine again as the reference compound, Malcolm and
colleagues used a physiological pharmacokinetic model (Fig. 5a) to describe the
effect of haemorrhage on lidocaine blood levels (Fig. 5b) and predicted tissue
disposition (Fig. 5c) [58, 59]. Our work possibly adds another dimension, in that we
showed for both aspirin and the organic nitrates that breakdown occurs in the blood
[60–62] and in extravascular tissues [62, 63], resulting in extraction across various
organs [64, 65], as illustrated in Fig. 5d. Malcolm and Steve Toon also conducted a
seminal drug structure pharmacokinetic study in which they described the
physiological pharmacokinetics for a series of barbiturates [66]. This work showed
that total barbiturate volume of distribution was relatively constant but that protein
binding and unbound barbiturate volume of distribution increased with lipophilicity
(Fig. 5e), consistent with an underlying increased tissue afﬁnity [66]. In contrast,
the relationship for clearance was complex and mainly due to renal and hepatic
elimination for low and high lipophilicity, respectively (Fig. 5f). A hepatic blood
ﬂow limitation applied for the highest homologs, whereas metabolism of the lowest
homologs was determined by the stereochemistry of position 5 on the barbituric acid
ring. Renal clearance decreased with increasing lipophilicity as a consequence of
increased tubular reabsorption (Fig. 5f) [66].
Pharmacokinetics in the perfused rat liver
The manner in which alterations in physiological states, such as organ blood
ﬂow, degree of drug binding within blood, and hepatocellular enzymatic
activity, inﬂuence the hepatic handling of drugs and hence their oral
availability is poorly understood [67]
Malcolm also saw the wisdom of studying solute disposition in isolated organs so
as to excluding varying blood ﬂow, systemic feedback and recirculation effects. His
Fig. 5 a A blood perfusion model used to describe the disposition kinetics of lidocaine in the monkey
and man (reprinted by permission from Macmillan Publishers Ltd: Clinical Pharmacology and
Therapeutics [59], copyright 1974). b Arterial blood concentrations of lidocaine in a normal and
subsequently bled rhesus monkey, with superimposed perfusion model simulation following a bolus
(10 mg) and a constant infusion (100 lg/kg/min) (reprinted by permission from Macmillan Publishers
Ltd:[58] Clinical Pharmacology and Therapeutics, copyright 1974). c Perfusion model simulation of the
distribution of lidocaine in various tissues in man after a 1 min injection of 100 mg in a 70 kg man
(reprinted by permission from Macmillan Publishers Ltd: [58] Clinical Pharmacology and Therapeutics,
copyright 1974). d Extraction of nitroglycerin across various organs of the sheep after intravenous
infusion (adapted from [65]). e Semilogarithmic plot of barbiturate total and unbound volume of
distribution at steady state against lipophilicity, as deﬁned by the logarithm of the octanol water partition
coefﬁcient (log P) (adapted from [66]). f Relationship between barbiturate total blood and renal clearance
and lipophilicity, as deﬁned by the logarithm of the octanol water partition coefﬁcient (log P) (adapted
from [66])
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extension of his work at the subcutaneous site, if both are seen as isolated organs.
Malcolm and Sandy had shown the disposition of lidocaine and its metabolite
MEGX was better described by a ‘‘well-stirred’’ than by a ‘‘tube’’ model [67–69].
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the liver was also a topic that I embarked on during my time at Manchester with
Malcolm. This occurred during the years 1983 to 1984 and were an eventful time for
my family and I as it was our ﬁrst time out of Australia and I was taking my ﬁrst
(and as it has proved to be so far, only) sabbatical leave. I had organised to spend
most of my time with Malcolm but had also organised to spend some time in
Clinical Pharmacology at Guy’s Hospital in London and to also visit various
institutions in Europe. It was during my time with Malcolm that I met and spent
time with Dawn and a fellow Australian Leon Aarons and his family as well as
others in Malcolm’s team. During my family’s sojourn to Europe in the middle
of this leave, we ventured behind the then Iron Curtin to meet Michael Weiss
and his family (a separate ‘mystical’ story), and one also leading to a long term
collaboration.
Malcolm had originally planned for me to do a series of experiments on protein
ﬂux from the blood into tissues across the capillaries but soon realised that my
interest lay in modelling. He therefore raised with me the controversial question of
what model should we be using to describe extraction in the liver. The experimental
steady state extraction data, in general, supported a well stirred (also called venous
equilibrium) model, whereas pragmatically, the liver physiology was more
consistent with a series of hepatic blood vessels (sinusoids) being described by a
tube model. One of the important ﬁrst steps Malcolm made was in giving me every
relevant American Journal of Physiology article on solute disposition in the liver he
came across. This was a crucial ﬁrst step as it encouraged me to read outside my
usual area of the pharmaceutical sciences. I know that I tried every modelling ‘trick’
I knew and got to a ‘desperation’ stage when I left for my scheduled trip to Europe.
It was then on the way back that the ‘obvious’ occurred to me. Maybe the
distribution of blood ﬂows was not exponential as assumed by the well stirred
model, nor a single value as assumed by the tube model nor a normal distribution as
assumed by a distributed form of the model introduced by Luxon and Forker [70]?
Could it be a log normal distribution? Koo et al. [71] had published blood cell
velocities in 515 sinusoids. When we analysed this data as a cumulative probability
distribution, we found that the data was better described by a log-normal than a
normal plot [72]. Further, we also found that the outﬂow concentration response–
time data for labelled red blood cells and albumin injected into a perfused liver as a
bolus by one of Malcolm’s PhD students (Anis Ahmad) was a skewed distribution
[72]. This led us on a chase looking for all models that may be applicable to such
phenomena and could also describe the outﬂow concentration–time proﬁles for
extracted drugs in organs. I ended up in the University of Manchester Institute for
Science Technology (UMIST) library, housed in a ‘grimy red-brick gothic structure’
in the centre of the city. I learned that the most widely used models in chemical
reaction engineering was the convection–dispersion model, often just called the
dispersion model, and the tank-in-series model [73, 74]. The dispersion model
generated an inverse Gaussian distribution of residence times–a similar skewed
shape to a log normal distribution. As shown in Fig. 6, this model gives a skewed to
the right outﬂow distribution after an impulse-response or bolus input. This, to me,
was an important insight as almost all studies seeking to discriminate between
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outﬂow concentrations. The other contemplated tank-in-series model generates a
gamma distribution, which is also a skewed distribution. The important realisation
was that one should not be assuming a model but rather letting the physiology deﬁne
the model. Again, the Box quote (op. cit.) is applicable.
One of the other realisations for me is that other disciplines often providing a
platform that can be used to develop our science. The convection–dispersion model
has its origins from the Chemistry Nobel Laureate Irving Langmuir’s second paper
in 1908 [75] and has been used in a wide range of areas including chemical reaction
engineering [76], meteorology [77], oceanography [78], soil science [79] and so on.
In addition, as had been realised for many years by the physiologists and chemical
engineers, one also needed to inject non-extracted markers as a bolus input to a
system to describe the various spaces in an individual organ such as the heart, liver
and kidney [80] or chemical reactor [76]. Indeed, Goresky had elegantly shown that
the impulse-response proﬁles for various markers can be superimposed if the
differences in their volumes can be corrected for [81]. As shown in Fig. 7a, the
convection–dispersion model describes that data very closely. One of the major
lessons that I learned from Malcolm was ‘‘to write for one’s reader and not for
Fig. 6 Comparison of different models of hepatic elimination (adapted from [72, 82, 90, 109–117, 171])
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123oneself’’. It is this insight that led to Malcolm’s suggested dispersion and efﬁciency
numbers so that the dispersion model was characterised and readily understood in
physiological pharmacokinetic terms.
The dispersion number derived from Goresky’s data was 0.12 (Fig. 7a),
intermediate between the well stirred model value of inﬁnity and tube model value
of zero [82]. Thus, the dispersion model was an intermediate model and the work to
date had been on comparing the extremes of this model. Importantly, when one ﬁts
steady state data and allows the dispersion number to vary, one obtains an
intermediate, if not a precise a value. For instance, the dependence of chromic
phosphate hepatic availability on liver ﬂow rate has a dispersion number of
0.35 ± 0.24 (Fig. 7b) whereas the hepatic availability for diazepam varies with
fraction unbound in plasma with a dispersion number of 0.29 ± 0.23 (Fig. 7c) [83].
In addition, the formation of metabolites [84] (Fig. 7d) and the correspondence of
perfused liver availability and in vitro microsomal enzyme activity [85] (Fig. 7e)
are consistent with intermediate dispersion numbers. The importance of the latter is
in scaling up human microsomal and hepatocyte data to predict hepatic extraction in
vivo as exempliﬁed by Sugiyama’s group [86, 87] and others [88]. It should also be
noted that the well stirred and parallel-tube models are the asymptotic solutions for
the dispersion model and that, when the availability in the liver is high (F[0.6),
one can show that the predicted availability for all models is similar [72].
It would be remiss of me not to acknowledge also the extensive and continuing
work on modelling of drug disposition in the liver undertaken by Sandy Pang, Carl
Goresky, Yuichi Sugiyama, Frank Burzynski, Andreas Schwab, Ludvik Bass, Tony
Bracken, Yuri Anissimov, Peter Robinson, Bruce Luxon, Leigh Forker, Denis
Morgan and colleagues using a physiological ‘segregated’’ transit time approach
that contrasts with the micromixing that is assumed for the convection–dispersion
model in the liver and the ‘‘tank-in-series’’ model described by Dick Weisiger, Gray
and Tam and by us. As Malcolm, John Donaldson (great applied mathematician
and, incidentially, father of Princess Mary of Denmark) and I showed, the choice of
an overall micromixing or segregated transit time does not affect outﬂow
predictions for linear kinetics [183]. It does however, matter for non-linear kinetics
as can be seen by comparing inﬂow into a tank in series with a tube with inﬂow into
a tube in series with a tank. Notably, also, the morphological organisation of the
liver is characterised by high intervascular mixing in the periportal (zone 1) region
but mainly segregated vascular ﬂow in the central (zone 3 region). One possible
pharmacokinetic hypothesis for the arrangement is that an efﬁcient ‘‘ﬂattening’’ of
plasma concentrations brought about by well-stirred conditions (Fig. 6) is needed in
the periportal region to limit exposure of the cells to drug and metabolite, especially
Fig. 7 a Output fraction versus time data of Goresky and the line of best ﬁt for mixed boundary model
(adapted from [81]). b Availability of colloidal chromic phosphate across the isolated perfused rat liver as
a function of blood perfusate ﬂow rate (data of Brauer et al. [172]) [83]. c Availability of diazepam across
the isolated perfused rat liver against fraction diazepam unbound (data of Rowland et al. [173]) [83].
d Residual plot for (ﬁlled diamond) well stirred model, (ﬁlled square) parallel-tube and (open circle)
dispersion models for apparent availability of the metabolite (acetaminophen) generated from its
precursor (phenacetin) [84]. e Availabilities (F) observed after perfusion of drugs through rat isolated
perfused livers versus the estimated efﬁciency number (RN) determined from in vitro microsomal data.
(adapted from [85]
c
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123as much drug metabolism occurs in zone 3 [89]. The segregated ‘‘tube’’
arrangement would allow more efﬁcient extraction in zone 3.
Our work on heterogeneity in liver kinetics [183] as well as nonlinear models
[90] is an area developed greatly and contributed to by Sugiyama’s group [86, 87]
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123and others [88]. There has been some controversy on what boundary conditions are
the most appropriate for use with the dispersion model [91, 92]. Malcolm and his
colleagues have made the last comment on this issue and, in noting the pros and
cons of the closed conditions (favoured in providing mass conservation at the
boundary) and mixed conditions (ease of its analytical form), suggest that the two
models give essentially equivalent ﬁts and dispersion numbers [93]. My group has
moved, inﬂuenced by Michael Weiss, to using an empirical dual inverse Gaussian
function that best describes the outﬂow proﬁles after bolus injections into the liver
[94] combined with a two compartment model that enables the relative importance
of permeability, diffusion and binding in the cells to be dissected out [95]. With
Yuri Anissimov, we have also developed a compartmental model for hepatic
elimination that accurately describes the observed vascular dispersion [96], but our
application of this model has, to this stage been limited [97].
Over the last two decades, both Malcolm’s and my group have had a major
emphasis on gathering data using the impulse-response technique in the in situ
perfused liver and in analysing data using the two compartment dispersion or related
vascular residence time model, taking into account the effects of catheter transit
times (Fig. 8a). The use of a bolus input has enabled the effect of vascular
dispersion and two compartment distribution in the liver (Fig. 8b) to be dissected
out using a vascular reference to deﬁne the vascular space and vascular dispersion
(Fig. 8c). To my knowledge this is the only effective way to separate out the role of
hepatocyte permeability as a determinant in hepatic pharmacokinetics. Malcolm’s
group has shown, for instance, that the hepatocyte permeability surface area product
increases with lipophilicity but that the dispersion number is independent of the
compound studied [98, 99]. This ﬁnding conﬁrms that the dispersion number is a
measure of the variation in residence times of solutes in the hepatic vasculature. In
other studies, Malcolm’s group has examined hepatic disposition of salicylate [100],
the effect of varying plasma [101, 102] and hepatic tissue binding [103], as well as
the role of the dual liver blood supply [104] and erythrocyte binding [105]o n
hepatic disposition kinetics. My group’s work has taken a slightly different track
and concentrated on solute structure-hepatic disposition relationships in normal and
in diseased livers. We have added to Malcolm’s work to show in our latest analysis
with 38 compounds that the permeability surface area product was dependent on
both lipophilicity and either the number of hydrogen bonding groups or the polar
Fig. 8 a Impulse-response technique showing the change in the shape of the impulse on passage through
catheters and a perfused organ. b Outﬂow proﬁle of a vascular reference (sucrose) and the drug atenolol in
a perfused rat liver (adapted from [113]). c Convection–dispersion model showing the processes of
vascular dispersion in hepatic sinusoids, distribution into and from, binding and clearance in hepatocytes
[171]. d Permeability surface area product (log PS)predicted for 38 drugs entering hepatocytes in perfused
livers can be related to observed values log PSobserved using (ﬁlled diamond) solute lipophilicity (log Papp)
alone (r
2 = 0.62) or, even better, (ﬁlled square) both solute lipophilicity and number of hydrogen
bonding groups (r
2 = 0.76), or (open circle) solute lipophilicity and polar surface area (r
2 = 0.75)
(adapted from [106]). e In diseased livers both lipophilicity (deﬁned by log Papp) and liver ﬁbrosis
(deﬁned by a computerised ﬁbrosis index (FI) derived from histology slides) deﬁne permeability surface
area products (PS) in the perfused rat liver: open circle normal group; ﬁlled diamond CCl4 treated group,
ﬁlled square alcohol treated group (log PS = 1.647 - 0.028FI ? 0.08 log Papp: p = 0.001, r
2 = 0.844,
n = 30) (adapted from [113])
c
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123surface area, but not the molecular size of the solutes (Fig. 8d) [106]. The lack of
solute dependency on size contrasts with transport of solutes through skin where
solute size is dominating [42]. Other studies include protein binding [107],
interspecies scaling [108], liver regeneration [109], metabolite kinetics [110, 111],
binding, ion trapping and disease [112–117]. In addition, we have examined
saturable uptake of digoxin and its inhibition by rifampicin [118]. Our work in the
diseased liver suggests that the hepatic permeability surface area product depends
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pathophysiology, as deﬁned by a computerised ﬁbrosis index derived from histology
slides (Fig. 8e). More recently, Tony Hunt has worked with us to apply his group’s
in silico autonomous software object models that allow the hepatic morphology and
transported events to be simulated in a physiologically based, mechanistically
realistic, in silico liver. We have been able to then use this in silico model to
describe their disposition in normal and diseased livers [119–121].
Let us return to the original question that led to the development of the dispersion
model, the ability to predict the extraction of highly extracted drugs. Currently, two
approaches are being taken. One is to ignore that a substantial difference exists
between the predicted and observed values using the well stirred model [122].
In the end, it is about changing paradigms as Malcolm has most recently pointed
out [123].
Pharmacokinetics in other perfused organs
Physiologically-based pharmacokinetics: academic curiosity or the holy grail
to prediction? Why do we get the proﬁles we see? Can we predict
quantitatively events in humans from in vitro, animal and other information?
Can we explain differences across compounds? Can we predict likely
variability in target patient population under clinically realistic conditions?
Malcolm Rowland 2009
Three different models described in 1968 set the scene for seeking to better
understand physiological pharmacokinetics at a more basic level.
Malcolm along with Sid Riegelman started questioning the one compartment
pharmacokinetic model [124]. Ken Bischoff and Bob Dedrick suggested that the
pharmacokinetics for thiopental could be described by an a priori mathematical
pharmacokinetic model that included blood ﬂows, tissue volumes, lipid solubility,
protein binding and metabolism [125]. Perl and Chinard described a convection–
diffusion model to describe solute disposition in the kidney in 1968 [126]. This
model is identical to the convection–dispersion model we described for the liver,
except that the terminology is different. The need to apply a convection dispersion
model in describing renal clearance of drugs has yet to be established. It could be
argued that, for most drugs, the well stirred model is adequate in describing renal
clearance. Indeed, Malcolm’s group used a simple physiologically based model of
tubular reabsorption to relate the renal clearances of a homologous series of six
5-substituted barbituric acids, of varying lipophilicity, in a recirculating isolated
perfused rat kidney preparation [127]. In addition, Malcolm, with Stephen Hall, has
also conducted a number of studies in the perfused kidney, emphasising the role of
protein binding [128, 129].
We began looking at the application of the dispersion model to other organs and
began by deﬁning the physiological spaces in the perfused leg under differing
physiological conditions [130] and recognising the combined importance of
vascular dispersion, tissue partitioning and tissue diffusion [95]. Figure 9a shows
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123Fig. 9 a Vascular dispersion in a muscle capillary bed and drug distribution from the capillaries into the
tissue (adapted from [95, 131, 137, 174, 175]). b Using the stochastic two-phase model ﬁt (dashed line)
for perfusate outﬂow concentration–time proﬁle (open circle) for propranolol to show that the resulting
predicted amount of propranolol in muscle tissue (solid line) is similar to that measured directly in muscle
(ﬁlled diamond) (adapted from [137]). c Predicted human venous concentration–time proﬁles after
intravenous administration based on the rat whole body dispersion model, showing an oscillation in the
initial 15 min (adapted from [145]). d Excellent linear relationship between predicted and experimentally
determined unbound partition coefﬁcients Kpu between tissue and plasma for disparate compounds
(7 very weak bases, 20 acids, 4 neutral drugs, 2 group 2 zwitterions and 6 group 1 zwitterions in 13 rat
tissues). The dashed lines represent 82% of 314 predictions (adapted from [154]). e In vivo imaging of
ﬂuorescein uptake into rat liver cells by multiphoton tomography [156]
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blood in the organ, permeation from the blood into tissue and diffusion in tissue. We
then applied this information to describe the disposition of diazepam, lidocaine and
antipyrine in the isolated perfused rat hindlimb [131]. We later showed that a similar
dispersion existed in the perfused human leg [132]. One practical application was in
trying to estimate the optimal perfusion conditions for administering and washing
out a cytotoxic agent whilst the limb bearing the melanoma(s) was separated from
the rest of the body [133]. In a second application, we also measured drug levels in
the tumour and tissue using microdialysis [134, 135]. We also applied this perfused
limb model to study the uptake of solutes of different protein binding into
underlying tissue after topical application [136]. Our data suggests that transport
into tissues is both perfusion and tissue binding limited, the latter being most
evident for the highly bound diclofenac where signiﬁcant diclofenac was eluted in
albumin containing but not dextran containing perfusate. In general, the outﬂow
proﬁle for a solute bound to perfusate correlates with its uptake into muscle, the site
for most uptake, and not into fat or skin (Fig. 9b) [137]. However, consistent with
events shown in Fig. 8a, Anne Heatherington and Malcolm showed that intravas-
cular distribution in the hindlimb after bolus administration can be overshadowed by
events in the connecting tubing and cannulas, resulting in discrepancies between
bolus and infusion pharmacokinetics [138]. Malcolm’s group has also applied the
dispersion model to describe the disposition of markers and a series of barbiturates
in the perfused hind leg [139].
We also investigated the importance of dispersion in the human placenta [140].
The perfused head proved to be a more challenging organ as we were unable to
distinguish uptake between the brain and other parts of the head [141, 142].
Recently, we have described disposition in the pancreas [143]. Most recently, we
have described the disposition of solutes in the perfused rat lung [144]. The
eventual outcome of bringing these various organs together is a whole-body
physiologically based pharmacokinetic model based on dispersion concepts and
to scale it to man in vivo [145]. The human venous outﬂow proﬁles were
characterised by the oscillation in venous and arterial blood ﬂow at early times as
reported in the anaesthesiology literature, as illustrated in Fig. 9c. At longer times
there was a build up of drugs in the skeletal muscle, skin, and fat and was better
able to accurately predict the distribution of drugs in the body than the
conventional well-stirred organ whole-body PBPK model. In our experience,
similar proﬁles, with much less computation, can be achieved by representing each
organ with a three compartment in series model and interlinking the organs as in
the classical physiological PBPK model. It is possible, however, that the dispersion
generated by the varying ﬂows to individual organs will prove to be the major
determinant of whole body dispersion [146] rather than the vascular dispersion in
individual organs. Indeed, Michael Weiss has generated a similar proﬁle to that in
Fig. 9c for the whole body based on cardiac output and systemic transit time
dispersion [147].
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The alternative to trying to understand what happens in the individual organs of the
body and resynthesising them back into the body is to study drug disposition in
organs directly in vivo. This latter approach was reported by Malcolm’s group in
1998 as basis for evaluating the contribution of structural and physicochemical
properties to pharmacokinetics. They studied the distribution kinetics of nine
5-alkyl-5-ethyl barbituric acids in arterial blood and 14 tissues (lung, liver, kidney,
stomach, pancreas, spleen, gut, muscle, adipose, skin, bone, heart, brain, testes)
after i.v. bolus administration in rats using well-stirred organ compartments and
assuming that either permeability rate limitation or perfusion rate limitation may be
involved in the distribution processes [148]. Muscle accounted for * 50% of the
total unbound volume of distribution for all compounds. This data was then
analysed using tissue-to-unbound plasma distribution coefﬁcients for each of the 14
rat tissues in terms of their octanol to water partition ratio, P, binding capacity of
each tissue and its water content [149]. Confounders include albumin diffusion
[150] and lipophilic solutes [151]. Later work included the benzodiazepines [152].
This work was then extended to the predictability of tissue-to-plasma water
partition coefﬁcients for 7 very weak bases, 20 acids, 4 neutral drugs and 8
zwitterions in rat adipose, bone, brain, gut, heart, kidney, liver, lung, muscle,
pancreas, skin, spleen and thymus [153, 154]. Expressions were developed that
recognise solubility in tissue water, partitioning into neutral lipids, neutral
phospholipids and other sites as well as drug ionisation). Interestingly, in their
latest paper in the series, Trudy Rodgers and Malcolm found a prediction for
binding restricted to muscle was similar to that using individual tissues and was
high in rats and humans [155]. Figure 9d shows that their modelling has provided
an excellent description of unbound partitioning coefﬁcients for a series of
heterogeneous compounds.
The dilemma remains—what is the best way forward. My group is adopting three
key approaches. One is to image events as they occur in individual organs in space
and time in vivo [156] (Fig. 9e). The second is to sample those organs with time.
Our group has used blood and destructive tissue sampling (Fig. 9b) as well as
cutaneous microdialysis [134, 135] to deﬁne the time course of drugs in organs.
Data analysis involves using either a mechanistic physiological pharmacokinetic
model [64, 65, 137] or to use simulation spatiotemporal processing of solutes in
individual organs [119]. Interestingly, the convection–dispersion developed with
Malcolm underpins each approach. For instance, the dispersion process is seen on
the direct imaging of the liver. Unpublished work on the transport of solutes into
deeper tissues of human skin after topical application in vivo measured by
microdialysis suggests that a convection dispersion process is partly responsible for
the carriage of highly albumin bound drugs to deeper tissues. Finally, all of our in
vivo simulations include an empirical gamma function that mimics the dispersion
process.
Comments made by Malcolm in 2009 at the American Society of Clinical
Pharmacology and Therapeutics contextualises our work in the way that drugs may
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structure is common to all mammals and includes both physiological parameters,
such as blood ﬂow, tissue size, composition etc. that are independent of drug
(system properties) and compound speciﬁc parameters that must be overlaid onto
this system such as clearance, tissue afﬁnity, membrane permeability etc. Much is
now known about pharmacokinetic variability with intrinsic factors such as age,
genetics, gender, and extrinsic factors such as formulation, disease, co-medication,
environment, diet and nutrition) affecting tissue weight, composition, blood ﬂow,
enzyme and transporter activity as well as hepatic metabolism, biliary, renal,
gastrointestinal and lung function. Building mechanistic physiological pharmaco-
kinetic models by this approach, as emphasised by this overview, is essentially a
bottom up synthetic approach in which parameter variability is deﬁned by
determinants such as enzyme activity, organ size, age etc. I would suggest that a
futuristic opportunity is a combination of the synthetic in silico approach that Tony
Hunt has led [119–121, 157] and The Simcyp Population-based ADME Simulator
[158] led by Geoff Tucker and Amin Rostami to predict drug-drug interactions and
pharmacokinetics in clinical populations. Simcyp integrates existing human
physiological, genetic and epidemiological data base information with supplied in
vitro data to predict ‘real-world’ pharmacokinetics.
Malcolm also commented that population pharmacokinetics has been essentially
a parallel but top down approach. Population pharmacokinetics has its origins in
applying statistical methodology to reﬁne dosage regimens for individual patients
[159]. Today, population pharmacokinetics continues to apply a statistical
approach in analysing observed data with usually a simple compartmental
empirical but, sometimes, with semi-physiologic, pharmacokinetic model. Appro-
priate covariates are used to account for the variability in parameters. The
approach, now called pharmacometrics, has become a standard component in drug
development, in deﬁning exposure-responses in Phase II/III studies and in
satisfying regulatory agencies, such as the FDA and TGA, that a product is
sufﬁciently efﬁcacious and safe to be approved for release into the general human
population. A major limitation in the approach is that Phase III studies rarely have
the statistical power required to conﬁdently assess the quantitative signiﬁcance of
potential covariates, and their correlations. Malcolm concluded his talk with a
future vision advocating a middle out approach, in which physiologically-based PK
models into all phases of clinical drug development. Models deﬁned by animal and
human physiological pharmacokinetic data should be reﬁned by preclinical
pharmacokinetic parameters from early experimental human/patient (Phase 0, I
and II) data. Phase III then becomes a conﬁrmation phase where the emphasis is on
whether observed concentration–time data are within expectations, instead of
searching for covariates and relationships. I have attempted to summarise the three
approaches in Fig. 10. Similar principles should apply to pharmacodynamics. The
eventual outcome should be a move to a better model-based drug development
paradigm.
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123Fig. 10 Diagrammatic comparison of the bottom up synthesised physiological pharmacokinetic models
approach to drug development, including microdosing, with the top down population pharmacokinetic
approach and the middle out approach that seeks to bring the bottom up and top down approaches
together. Similar principles are applied in extension to pharmacokinetic–pharmacodynamic relation-
ships [176–179] (broader population histogram redrawn from [176]; events at steady state redrawn
from [179])
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The idea of applying the concept of clearance, well established in renal
physiology, to drug kinetics was of singular importance and one to which
Malcolm Rowland and Grant Wilkinson made the major contribution. [160].
The story I have presented to date represents only a small fraction of the total
impact Malcolm has had on our discipline and on me, in particular. There are many
other stories to tell about Malcolm’s contribution to the broader discipline of
pharmacokinetics and pharmacodynamics, including the development of clearance
concepts [161], the application of pharmacokinetics to the clinical situation [162,
163], understanding toxicokinetic principles [164] and using pharmacokinetics in
drug development [165–167] and making pharmacokinetics easier to understand
[168]. I will leave it to others to tell those stories!
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